Clinical Trial Update: Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation

View source ↗

Summary

A completed clinical trial evaluating a weekly effervescent tablet formulation of alendronate after denosumab discontinuation in postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Denosumab (denosumab)
• alendronate (alendronate)

Snippet

Sponsor: 251 Hellenic Air Force & VA General Hospital | Conditions: Postmenopausal Osteoporosis | Status: COMPLETED